Literature DB >> 31307634

Differentiation of atypical non-functional pancreatic neuroendocrine tumor and pancreatic ductal adenocarcinoma using CT based radiomics.

Ming He1, Zhenyu Liu2, Yusong Lin3, Jianzhong Wan3, Juan Li1, Kai Xu1, Yun Wang1, Zhengyu Jin1, Jie Tian4, Huadan Xue5.   

Abstract

PURPOSE: To develop and validate an effective model to differentiate NF-pNET from PDAC.
MATERIALS AND METHODS: Between July 2014 and December 2017, 147 patients (80 patients with PDAC and 67 patients with atypical NF-pNET) with pathology results and enhanced CT were consecutively enrolled and chronologically divided into primary and validation cohorts. Three models were built to differentiate atypical NF-pNET from PDAC, including a model based on radiomic signature alone, one based on clinicoradiological features alone and one that integrated the two. The diagnostic performance of the three models was estimated and compared with the area under the receiver operating characteristic curve (AUC) in the validation cohort. A nomogram was used to represent the model with the best performance, and the associated calibration was also assessed.
RESULTS: In the validation cohort, the AUC for differential diagnosis was 0.884 with the integrated model, which was significantly improved over that of the model based on clinicoradiological features (AUC = 0.775, p value = 0.004) and was comparable to that of the model based on the radiomic signature (AUC = 0.873, p value = 0.512). The nomogram representing the integrated model achieved good discrimination performances in both the primary and validation cohorts, with C-indices of 0.960 and 0.884, respectively.
CONCLUSION: The integrated model outperformed the model based on clinicoradiological features alone and was comparable to the model based on the radiomic signature alone with respect to the differential diagnosis of atypical NF-pNET and PDAC. The nomogram achieved an optimal preoperative, noninvasive differential diagnosis between atypical pNET and PDAC, which can better inform therapeutic choice in clinical practice.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Differential diagnosis; Multidetector computed tomography; Neuroendocrine tumor; Pancreatic ductal carcinoma; Radiomics

Mesh:

Year:  2019        PMID: 31307634     DOI: 10.1016/j.ejrad.2019.05.024

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  11 in total

Review 1.  GEP-NET radiomics: a systematic review and radiomics quality score assessment.

Authors:  Femke C R Staal; Else A Aalbersberg; Daphne van der Velden; Erica A Wilthagen; Margot E T Tesselaar; Regina G H Beets-Tan; Monique Maas
Journal:  Eur Radiol       Date:  2022-07-26       Impact factor: 7.034

2.  MRI Feature-Based Nomogram Model for Discrimination Between Non-Hypervascular Pancreatic Neuroendocrine Tumors and Pancreatic Ductal Adenocarcinomas.

Authors:  Jiake Xu; Jie Yang; Ye Feng; Jie Zhang; Yuqiao Zhang; Sha Chang; Jingqiang Jin; Xia Du
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

3.  A deep learning algorithm to improve readers' interpretation and speed of pancreatic cystic lesions on dual-phase enhanced CT.

Authors:  Xiheng Wang; Zhaoyong Sun; Huadan Xue; Taiping Qu; Sihang Cheng; Juan Li; Yatong Li; Li Mao; Xiuli Li; Liang Zhu; Xiao Li; Longjing Zhang; Zhengyu Jin; Yizhou Yu
Journal:  Abdom Radiol (NY)       Date:  2022-03-27

4.  Radiomics Analysis Based on Diffusion Kurtosis Imaging and T2 Weighted Imaging for Differentiation of Pancreatic Neuroendocrine Tumors From Solid Pseudopapillary Tumors.

Authors:  Yan-Jie Shi; Hai-Tao Zhu; Yu-Liang Liu; Yi-Yuan Wei; Xiu-Bo Qin; Xiao-Yan Zhang; Xiao-Ting Li; Ying-Shi Sun
Journal:  Front Oncol       Date:  2020-08-21       Impact factor: 6.244

Review 5.  Pancreas image mining: a systematic review of radiomics.

Authors:  Bassam M Abunahel; Beau Pontre; Haribalan Kumar; Maxim S Petrov
Journal:  Eur Radiol       Date:  2020-11-05       Impact factor: 5.315

Review 6.  Update on quantitative radiomics of pancreatic tumors.

Authors:  Mayur Virarkar; Vincenzo K Wong; Ajaykumar C Morani; Eric P Tamm; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2021-07-22

Review 7.  The impact of radiomics in diagnosis and staging of pancreatic cancer.

Authors:  Calogero Casà; Antonio Piras; Andrea D'Aviero; Francesco Preziosi; Silvia Mariani; Davide Cusumano; Angela Romano; Ivo Boskoski; Jacopo Lenkowicz; Nicola Dinapoli; Francesco Cellini; Maria Antonietta Gambacorta; Vincenzo Valentini; Gian Carlo Mattiucci; Luca Boldrini
Journal:  Ther Adv Gastrointest Endosc       Date:  2022-03-16

Review 8.  Setting the Research Agenda for Clinical Artificial Intelligence in Pancreatic Adenocarcinoma Imaging.

Authors:  Megan Schuurmans; Natália Alves; Pierpaolo Vendittelli; Henkjan Huisman; John Hermans
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

9.  CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.

Authors:  Damiano Caruso; Michela Polici; Maria Rinzivillo; Marta Zerunian; Ilaria Nacci; Matteo Marasco; Ludovica Magi; Mariarita Tarallo; Simona Gargiulo; Elsa Iannicelli; Bruno Annibale; Andrea Laghi; Francesco Panzuto
Journal:  Radiol Med       Date:  2022-06-18       Impact factor: 6.313

10.  Application of CT-Based Radiomics in Discriminating Pancreatic Cystadenomas From Pancreatic Neuroendocrine Tumors Using Machine Learning Methods.

Authors:  Xuejiao Han; Jing Yang; Jingwen Luo; Pengan Chen; Zilong Zhang; Aqu Alu; Yinan Xiao; Xuelei Ma
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.